Research Advances in the Role of the Poly ADP Ribose Polymerase Family in Cancer

被引：4
|
作者：
Sha, Huanhuan [1 ]
Gan, Yujie [1 ]
Zou, Renrui [1 ]
Wu, Jianzhong [2 ]
Feng, Jifeng [1 ]
机构：
[1] Nanjing Med Univ, Jiangsu Canc Hosp, Jiangsu Inst Canc Res, Dept Chemotherapy,Affiliated Canc Hosp, Nanjing, Peoples R China
[2] Nanjing Med Univ, Jiangsu Canc Hosp, Jiangsu Inst Canc Res, Res Ctr Clin Oncol,Affiliated Canc Hosp, Nanjing, Peoples R China
来源：
FRONTIERS IN ONCOLOGY | 2021年 / 11卷
关键词：
PARPs; ADP-ribosylation; cancer; mechanism; biological process; ENDOPLASMIC-RETICULUM STRESS; UNFOLDED PROTEIN RESPONSE; B-CELL LYMPHOMAS; BREAST-CANCER; POLY(ADP-RIBOSE) POLYMERASES; COLORECTAL-CANCER; MYELOID-LEUKEMIA; TUMOR-SUPPRESSOR; OVARIAN-CANCER; PARP6; ACTS;
D O I：
10.3389/fonc.2021.790967
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Poly ADP ribose polymerases (PARPs) catalyze the modification of acceptor proteins, DNA, or RNA with ADP-ribose, which plays an important role in maintaining genomic stability and regulating signaling pathways. The rapid development of PARP1/2 inhibitors for the treatment of ovarian and breast cancers has advanced research on other PARP family members for the treatment of cancer. This paper reviews the role of PARP family members (except PARP1/2 and tankyrases) in cancer and the underlying regulatory mechanisms, which will establish a molecular basis for the clinical application of PARPs in the future.
引用
收藏
页数：11
相关论文
共 50 条
  • [21] Failure of Iniparib to Inhibit Poly(ADP-Ribose) Polymerase In Vitro
    Patel, Anand G.
    De Lorenzo, Silvana B.
    Flatten, Karen S.
    Poirier, Guy G.
    Kaufmann, Scott H.
    CLINICAL CANCER RESEARCH, 2012, 18 (06) : 1655 - 1662
  • [22] Neurological toxicities with poly (ADP-ribose) polymerase inhibitors in cancer patients: a systematic review and meta-analysis
    Jin, Wenfang
    Zhang, Zhifeng
    Sun, Wenxia
    Li, Jing
    Xiong, Wen
    JOURNAL OF CHEMOTHERAPY, 2024,
  • [23] Update on Poly ADP-Ribose Polymerase Inhibitors in Ovarian Cancer With Non-BRCA Mutations
    Xu, Qin
    Li, Zhengyu
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [24] Mechanism and current progress of Poly ADP-ribose polymerase (PARP) inhibitors in the treatment of ovarian cancer
    Zheng, Feiyue
    Zhang, Yi
    Chen, Shuang
    Weng, Xiang
    Rao, Yuefeng
    Fang, Hongmei
    BIOMEDICINE & PHARMACOTHERAPY, 2020, 123
  • [25] Niraparib hydrochloride. Poly [ADP-ribose] polymerase (PARP) inhibitor, Oncolytic.
    Gras, Jordi
    DRUGS OF THE FUTURE, 2013, 38 (10) : 679 - 685
  • [26] Differential and Concordant Roles for Poly(ADP-Ribose) Polymerase 1 and Poly(ADP-Ribose) in Regulating WRN and RECQL5 Activities
    Khadka, Prabhat
    Hsu, Joseph K.
    Veith, Sebastian
    Tadokoro, Takashi
    Shamanna, Raghavendra A.
    Mangerich, Aswin
    Croteau, Deborah L.
    Bohr, Vilhelm A.
    MOLECULAR AND CELLULAR BIOLOGY, 2015, 35 (23) : 3974 - 3989
  • [27] Poly(ADP-Ribose) Polymerase Inhibitor Inhibition in Ovarian Cancer A Comprehensive Review
    Moore, Kathleen N.
    Pothuri, Bhavana
    CANCER JOURNAL, 2021, 27 (06): : 432 - 440
  • [28] Novel poly-ADP-ribose polymerase inhibitor combination strategies in ovarian cancer
    McCann, Kelly E.
    CURRENT OPINION IN OBSTETRICS & GYNECOLOGY, 2018, 30 (01) : 7 - 16
  • [29] The emerging potential of poly(ADP-ribose) polymerase inhibitors in the treatment of breast cancer
    Drew, Yvette
    Plummer, Ruth
    CURRENT OPINION IN OBSTETRICS & GYNECOLOGY, 2010, 22 (01) : 67 - 71
  • [30] Clinical Trials of Poly(ADP-Ribose) Polymerase Inhibitors for Cancer Therapy: A Review
    Buege, Michael
    Mahajan, Pramod B.
    REVIEWS ON RECENT CLINICAL TRIALS, 2015, 10 (04) : 326 - 339
12345